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Introduction: Despite considerable benefits associated with current drug-eluting stents,
continued attention to the safety, efficacy, and deliverability of available drug-eluting stent
has led to the development of newer stent.
Methods: This study was a single-centre, prospective, non-randomized, first-in-man study
which included clinical follow-up data was collected at 1, 8 and 12 months after the
procedure. The study included 105 patients with de novo native coronary artery lesions
including multi-vessel disease treated with Supralimus-Core stent. Repeat angiography
was performed 8 months post-stent implantation.
Results: At quantitative coronary angiography 8-month luminal late loss was 0.39 0.33mm
in-stent and 0.33 0.35mmin-segment. The incidence of anymajor adverse cardiac event at
30 days, 8 months and 12 months was 1 (1%), 6 (6%) and 7 (7%) respectively.
Conclusion: This study demonstrates that the Supralimus-Core SES is a safe and effective
treatment for patients with obstructive coronary artery disease.
ClinicalTrials.gov ID: NCT00811616.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction production.7 It has also been demonstrated that thin strutEndoluminal metallic stents are the preferred treatment
during percutaneous coronary interventions because of their
proven superiority over balloon angioplasty.1e3 In bare metal
stainless steel stents restenosis still occurs in 20%e40%
patients.4e6 The principal cause of in-stent restenosis is neo-
intimal hyperplasia resulting from proliferation and migra-
tion of smooth muscle cells and extracellular matrixrformed: Max Devki Devi H
1 11 26510050.
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2012, Cardiological SocietCobalt-Chromium (Co-Cr) stents may lead to lower restenosis
than thick strut stainless steel stent. Stent-based drug
delivery has resulted in a revolutionary change in the field of
percutaneous intervention, with recent clinical trials of
paclitaxel-eluting stents (PES) or SES demonstrating prom-
ising results in the treatment of de novo coronary lesions.8
Although the first generation of DES have drastically
reduced rates of restenosis and revascularization,9e12eart & Vascular Institute, 2, Press Enclave Road, Saket, New Delhi
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presence of a permanent non-degradable polymer may
contribute to late and very late stent thrombosis in some cases
as a result of delayed healing, inflammatory and hypersensi-
tivity reaction in some cases.16e20 To address this issue, a new
generation of DES has been developed, incorporating biode-
gradable, biocompatible polymers as vehicles for drug
delivery. The polymers retain the drug to the vessel wall over
days and then degrade over months to biologically inert end
products. This remains behind a BMS in a hope to avoid the
potentially harmful effects of permanent polymers.20
Supralimus-Core (Sahajanand Medical Technologies Pvt.
Ltd., Surat, India) uses L605 Co-Cr alloy as its stent platform
which is coated with a biodegradable polymer to deliver
sirolimus. The present ‘First-in-Man’ study was undertaken to
establish safety and efficacy of using Supralimus-Core stent
in PCI of real life patients with angiographic and clinical
follow-up.
MAXIMUS study (A First-In-Man Study of Sirolimus-
Eluting, Biodegradable Polymer Coated Cobalt-Chromium
Stent) was a prospective, non-randomized, singlecentre
FIM study with Supralimus-Core_ sirolimus-eluting coronary
stent system.2. Methods
2.1. Study design and patient population
Patients included in the study were more than 18 years of age,
with symptomatic ischaemic heart disease with de novo
stenotic coronary lesion with reference vessel diameter (RVD)
of 2.5 and 3.5 mm. The study included 49 (47%) patients
with multi-vessel disease and 12.83  7.0 mm lesion length.
The study was conducted in compliance with ICH-GCP and
the Declaration of Helsinki. The study protocol was approved
by the local hospital ethics committee. All the patients were
enrolled in study only after informed consent was being
signed. They were explained the risks and benefits of partici-
pations in study.
Patients were excluded if any of the following conditions
were present: General exclusion criteria: (1) Women of
childbearing potential; (2) impaired renal function (creati-
nine >2.0 mg/dl or 177 mmol/l); (3) any patient who has
a platelet count <100,000 cells/mm3 or >700,000 cells/mm3,
aWBC of<3,000 cells/mm3, or documented or suspected liver
disease (including laboratory evidence of hepatitis); (4)
recipient of heart transplant; (5) restenosis or significant
lesion in graft; (6) Patient with a life expectancy less than 12
months; (7) known allergies to aspirin, clopidogrel bisulphate
(Plavix), ticlopidine (Ticlid), heparin or cobalt chromium;
(8) any significant medical condition which in the investiga-
tor’s opinion may interfere with the patient’s optimal
participation in the study; (9) currently participating in an
investigational drug or another device study, or subject to
inclusion in another investigational drug or another device
study during follow-up. Angiographic exclusion criteria: (1)
Unprotected left main coronary artery disease with 50%
stenosis; (2) angiographic evidence of thrombus (thrombus
larger than half the diameter of the vessel and/or requiringother interventions such as angiojet, exciser, thrombolysis,
etc.); (3) Ejection fraction 30%.
2.2. Description of the study stent
Supralimus-Core (Sahajanand Medical Technologies Pvt.
Ltd., Surat, India) has L605 Co-Cr alloy as its stent platform
having strut thickness of 60 mm with biodegradable poly-
mers and drug load of 1.4 mg/mm2. About 70% of drug is
released within 7 days and remaining drug is released over
a period of 48 days. The coating layer comprises of drug
sirolimus blended together with biodegradable polymeric
matrix. This matrix includes different biodegradable poly-
mers e poly L-lactide, 50/50 poly-DL-lactide-co-glycolide and
polyvinyl pyrrolidone to control the drug elution from stent
coating. After releasing the drug within 48 days, these
polymers eventually degrades naturally and are excreted
from the body in the form of their metabolites. The average
coating thickness of Supralimus-Core stent is between 5
and 6 mm.
The Supralimus-Core stent wasmade available in lengths
of 8, 12, 16, 20, 24, 28 and 32mm and available diameters were
2.5, 3.0 and 3.5 mm. Total 105 consecutive patients were
included in the MAXIMUS study from July, 2006 to April, 2007.
2.3. Interventional procedure and adjunctive
medications
All patients were on aspirin in a dose of 75e150 mg at least
24 h prior to the procedure. A loading dose of 300 mg of
clopidogrel was given 24 h prior to procedure or 600 mg on
the day of the procedure was given to patients before
procedure. During the procedure initial dose of 70e100 IU/kg
bolus of heparin was given to the patient. Additional
heparin was used if necessary during procedure to achieve
activated coagulation time >250 s. Administration of GP IIb/
IIIa inhibitor was left to the investigator’s discretion.
Angiographic success was defined as 20% stenosis by
visual estimation.
Following PCI, recommended standard dual antiplatelet
regimens, every patient received daily minimum 150 mg
aspirin for 1 month and 75 mg thereafter for 1 year plus
minimum 75 mg clopidogrel for 1 year.
2.4. Follow-up
Patients were clinically followed-up at (1) 7 days window
period at 1 month, (2) 30 days window period at 8 months and
(3) 45 days window period at 12 months after the procedure.
The clinical follow-up consisted of either a telephone inter-
view or a clinic visit. Angiographic follow-up was performed
at 8 months (30 days).
2.5. Study endpoints and definitions
MACE was defined as the primary safety endpoint which was
defined as the incidence of cardiac death, myocardial infarc-
tion (Q-wave and non-Q-wave), emergent cardiac surgery and
clinically justified target lesion revascularization (TLR) at 30
days following index procedure. MI was defined as Q-wave MI
Table 1 e Baseline demographic characteristics.
Characteristics Supralimus-Core SES n ¼ 105
patients
Age (mean  SD, years) 58.8  10
Male, n (%) 83 (79.0%)
Diabetes mellitus, n (%) 39 (37.1%)
Insulin requiring, n (%) 7 (6.7%)
Non-insulin requiring, n (%) 32 (30.4%)
Hypertension, n (%) 50 (47.6%)
Smoker, n (%) 32 (30.4%)
Dyslipidemia, n (%) 37 (35.2%)
Previous MI, n (%) 35 (33.3%)
SES ¼ Sirolimus-Eluting Stent.
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with CK-MB levels elevated above normal) or non-Q-wave MI
(elevation of CK levels to 2 times upper normal limit with
CKeMB levels elevated above normal).
The primary efficacy endpoint was in-stent binary reste-
nosis rate at 8 months which determined by off-line Quanti-
tative Coronary Angiographic Analysis (QCA). Binary
angiographic restenosis was defined as a diameter stenosis
(DS) 50% at follow-up angiography.
Secondary efficacy end points were assessed as acute gain,
post-procedure minimum lumen diameter (MLD), post-
procedure percentage diameter stenosis and late loss at
follow-up, clinically justified TLR, angiographic and proce-
dural success. Late loss was defined as the difference between
MLD post-procedure and MLD at follow-up. TLR was clinically
justified if diameter stenosis was 50% (by off-line QCA) or if
the patient exhibited one of the following symptoms: (1)
recurrent angina pectoris, (2) ischaemia at rest or during
exercise (3) abnormal results of any invasive functional diag-
nostic test (e.g. Doppler flow velocity reserve, fractional flow
reserve).
Secondary safety endpoint was defined as device related
serious adverse events (SAEs) and angiographic sub-acute and
late stent thrombosis up to 12 months (standard definition of
stent thrombosis using standard Academic Research Consor-
tium (ARC) criteria used). The stent thrombosis is defined as
acute if it occurred between 0 and 24 h, sub-acute between
25 h and 30 days, late between 31 days and 1 year, and very
late beyond 1 year after stent implantation. With respect to
probability, stent thrombosis is defined as definite, probable,
or possible.Table 2 e Procedural and lesion characteristics.
Characteristics Supralimus-Core SES, n ¼ 194 lesions
Target coronary artery2.6. Data management and statistical analysis
Baseline and 8-month follow-up angiograms were evaluated
by an independent contract research organization (Cardial-
ysis, Westblaak 92, 3012 KM Rotterdam, The Netherlands). All
analysis was based on the intention-to-treat principle. The
stented segment refers to the stent and 5 mm proximal and
distal to the stent edges. The following data were obtained:
MLD, interpolated reference vessel diameter and percentage
diameter stenosis. The baseline characteristics (patient
demographics, cardiovascular disease history, other risk
factors, pre-procedure target lesion characteristics and
procedure characteristics) have been summarized with the
mean, standard deviation, median and range for continuous
variables and with frequencies and percentages for discrete
variables. MACE was reviewed and adjudicated by an inde-
pendent clinical events committee. QCA was analysed with
the SAS software.
LAD, n (%) 76 (39.2%)
RCA, n (%) 62 (32.0%)
Circumflex, n (%) 56 (28.8%)
Lesion classification (ACC/AHA class)
Type A, n (%) 6 (3.1%)
Type B1, n (%) 78 (40.2%)
Type B2, n (%) 96 (49.5%)
Type C, n (%) 14 (7.2%)
ACC ¼ American College of Cardiology; AHA ¼ American Heart
Association; SES ¼ Sirolimus-Eluting Stent.3. Results
3.1. Baseline patient characteristics and follow-up
The baseline demographics, procedural and lesion charac-
teristics of the MAXIMUS study population have been
summarized (Tables 1 and 2).3.2. Angiographic and clinical outcomes
Total 105 patients (194 lesions)were implantedwith 234 stents
with mean stent length of 19.72  9.2 mm. An average of 2.23
stents was implanted per patient and 1.2 stent implanted per
lesion. All angiograms were evaluated by readers blinded to
the study stent, by an independent core laboratory (Cardial-
ysis, Westblaak 92, 3012 KM Rotterdam, The Netherlands).
One-month and 12-month clinical follow-up were performed
in 101 (96%) patients. Eight-month angiographic follow-up
was performed in 84 (80%) patients (Table 3). The normality
of the distributions of in-stent late loss was tested with Kol-
mogoroveSmirnov test (KeS test: P ¼ 0.041) and right skew-
ness 1.06 (Fig. 1).
No in-hospital events were reported. The incidence of any
MACE at 30 days, 8 months and 12 months was 1 (1%), 6 (6%)
and 7 (7%) respectively. Two patients were underwent TVR.
Repeat revascularization at target lesion was done in 1 patient
at 8-month follow-up. There was one incidence of sub-acute
thrombosis and one incidence of late stent thrombosis
(Table 4).3.3. Deaths during follow-up
Total of 4 deaths (3 non-cardiac and 1 probable cardiac)
occurred during follow-up period. This death has been docu-
mented as cardiac death as per ARC definition. The 3 non-
cardiac deathswere due to brain haemorrhage,multiple organ
failure, and pyrexia of unknown origin.
Table 3 e Quantitative coronary angiographic analysis.
Supralimus-Core SES
Pre-procedure Post-procedure 8-month
follow-up
No. of lesions 172 194 152
Reference vessel diameter, mm
In-stent 2.48  0.5 2.63  0.46 2.37  0.40
In-segment e 2.55  0.49 2.33  0.43
Minimal luminal diameter, mm
In-stent 0.89  0.44 2.3  0.42 1.91  0.43
In-segment e 2.05  0.47 1.72  0.44
Late loss, mm
In-stent e e 0.39  0.33
In-segment e e 0.33  0.35
Diameter stenosis, %
In-stent 63.77  16.63 12.32  6.38 19.20  12.86
In-segment e 20.02  8.68 25.98  12.02
Binary angiographic restenosis, n (%)
In-stent e e 5 (3.3%)
In-segment e e 7 (4.6%)
Values expressed as number (%) or mean (SD).
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There were total 3 TVR/TLR up to 12 months. The decision to
perform further TLR or TVR after the 8 months angiographic
follow-up was left to the investigator’s discretion as per
protocol design.Fig. 1 e Distribution of4. Discussion
Efficacy of sirolimus-eluting stent using stainless steel plat-
form and biostable polymer has been well documented in
medical literature.10,21e24
The Co-Cr stent platform provides flexibility for easy
delivery, conformability and scaffolding that adapts vessel to
the blood. Hence using Co-Cr as stent platform is likely to
improve technical and procedural success of SES as well as
influence late loss and restenosis. Supralimus-Core stent has
a strut thickness of 60 mm (thin strut) which is also likely to
improve long-term angiographic result as has been shown in
ISAR STEREO study.25
The first generation SES has used permanent (non-
degradable) polymers. Persistence of polymers in the coronary
artery after the elution of drug may become the source of
inflammation in the artery. Thismay partly explain the higher
incidence of late and very late thrombosis. It is inherently
logical that disappearance of polymer after complete drug
elution would be highly desirable.26
ISAR-TEST 3 trial which compared outcomes of DES with
biodegradable-polymer, no-polymer, and permanent-polymer
SES showed best outcomes with biodegradable polymer
(revascularization at 1 year: 5.9%, 12.9%, 7.9%, respectively and
death or myocardial infarction at 1 year: 2.5%, 4.0%, and 3.5%,
respectively for biodegradable-polymer, no-polymer, and
permanent-polymer SES).27 The present study used biode-
gradable polymer as vehicle for sirolimus-eluting Co-Cr stent
showed excellent procedural success 100% and very low in-in-stent late loss.
Table 4 e Clinical outcomes at 30 days, 8 months and 12
months follow-up.
Supralimus-Core SES
30 days 8 months 12 months MACE
No. of patients 101 84 101 105
Deaths
Cardiac 0 1 0 1 (1%)
Non-cardiac 0 3 0 3 (3%)
TLR 0 1 0 1 (1%)
TVR 1 0 1 2 (2%)
CABG 0 0 0 0
Stent thrombosisa 1 1 0 2 (2%)
Values expressed as number (%).
a Stent thrombosis according to the ARC (Academic Research
Consortium) definition TVR ¼ Target Vessel Revascularization;
TLR ¼ Target Lesion Revascularization; CABG ¼ Coronary Artery
Bypass Grafting.
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 5 4 7e5 5 2 551hospital MACE. Long-term safety was also well demonstrated
at 1 yearwith lowMACE rate of 7% at 1 year. Long-term follow-
up is ongoing.
At 8-month follow-up, 84 patients received CAG, which is
comparable with other published trials.28,29 The study
demonstrated a late loss of 0.39  0.33 mm in-stent and
0.33  0.35 mm in-segment. This was somewhat higher than
previous studies of SESs with stainless steel platform (late
loss of 0.17  0.45 mm in the SIRIUS trial).30 This may have
happen because of complex demographic factors (e.g. Dia-
betes 37%, hypertension 48%, type C lesion 6.7%, 28 mm
lesion 20% and small vessel 3 mm 84%) might have
contributed to slightly higher late loss. Late loss is also not
higher in comparison to other Co-Cr platform drug-eluting
stents.29,31e34 However this slightly higher late loss at angio-
graphic QCA follow-up did not result in significant increase
in-binary restenosis rate. In fact the restenosis rate and TLR
were lower than study demonstrating relatively lower
angiographic late loss.
4.1. Study limitations
This study is limited by its non-randomized, single-centre
with moderate sample size. The follow-up period is limited to
1 year.5. Conclusions
In a cohort of real-world patient with significantly high
percentage of unfavourable demographic and angiographic
factors sirolimus-eluting Co-Cr Supralimus-Core stent
showed very low MACE rate, TLR and angiographic restenosis
at 1 year. Further longer-term follow-up would be desirable to
document very long safety and recommend preferred use of
biodegradable polymers for SES. The present study data
provides a strong foundation for a pivotal randomized trial of
the Supralimus-Core platform. Larger number of patient
studies will provide greater insight into the benefit of this
system in patients.Funding
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